Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 3: The effect of flow increase rate (FIR) on the in vitro drug release from the Pulmicort 200 Turbuhaler

International Journal of Pharmaceutics

Volumn 153, Issue 1, 1997, Pages 67-77

  De Boer, A H ^a   Bolhuis, G K ^a   Gjaltema, D ^a   Hagedoorn, P ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Asthma; Cascade impactor; COPD; FIR; Flow increase rate; In vitro deposition; PIFR; Pulmicort Turbuhaler

Indexed keywords

BUDESONIDE; TERBUTALINE;

ADULT; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG RELEASE; DRY POWDER; FEMALE; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PARTICLE SIZE; POWDER INHALER; PRIORITY JOURNAL; SPIROMETRY; VOLUNTEER;

EID: 0030795605     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(97)00097-5     Document Type: Article

References (22)

1. Borgström, L., Newman, S., Weisz, A., Morén, F., 1992. Pulmonary deposition of inhaled terbutaline: comparison of scanning gamma camera and urinary excretion methods. J. Pharm. Sci. 81, 753-755.
2. Borgström, L., Newman, S., 1993. Total and regional lung deposition of terbutaline sulphate inhaled via a pressurized MDI or via Turbuhaler. Int. J. Pharm. 97, 47-53.
3. Borgström, L., Bondesson, E., Morén, F., Trofast, E., Newman, S.P., 1994. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur. Respir. J. 7, 69-73.
4. Brown, P.H., Greening, A.P., Crompton, G.K., 1992. Peak inspiratory flow rates in acute asthma: are they adequate for efficient use of a Turbuhaler?. Thorax 47, 239P.
5. Brown, P.H., Ning, A.C.W.S., Greening, A.P., McLean, A., Crompton, G.K., 1995. Peak inspiratory flow through Turbuhaler in acute asthma. Eur. Respir. J. 8, 1940-1941.
6. De Boer, A.H., Gjaltema, D., Hagedoorn, P., 1995. Inhalation characteristics and air flow resistance of dry powder inhalers as preferred by healthy subjects. Eur. Respir. J. 8 (Suppl 19), 425S.
7. De Boer, A.H., Gjaltema, D., Hagedoorn, P., 1996a. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 2: Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int. J. Pharm. 138, 45-56.
8. De Boer, A.H., Gjaltema, D., Hagedoorn, P., 1996b. Necessary flow rates for maximum fine particle output from commercial dry powder inhalers (DPI's). Eur. Respir. J. Suppl 23, 206S.
9. De Boer, A.H., Winter, H.M.I., Lerk, C.F., 1996c. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 1: Inhalation characteristics, work of breathing and volunteer's preference in dependence of the inhaler resistance. Int. J. Pharm. 130, 231-244.
10. Engel, T., Heinig, H., Malling, H.-J., Scharling, B., Nikander, K., Madsen, F., 1989. Clinical comparison of inhaled budesonide delivered either via pressurized metered dose inhaler or Turbuhaler. Allergy 44, 220-225.
11. Engel, T., Heinig, J.H., Madsen, F., Nikander, K., 1990. Peak inspiratory flow and inspiratory vital capacity of patients with asthma measured with and without a new dry powder inhaler device (Turbuhaler). Eur. Respir. J. 3, 1037-1041.
12. Fuller, R., 1995. The Diskus™: a new multi-dose powder device efficacy and comparison with Turbuhaler™. J. Aerosol Med. 8 (Suppl 2), S11-S17.
13. Hill, L.S., Higgins, A.J., 1991. The acceptability of two powder inhalers compared in patients with well controlled chronic asthma. Eur. Respir. J. 4 (Suppl 14), 556S.
14. Ifversen, M., Bisgaard, H., Klug, B., Skamstrup, K., Sumby, B., 1995. Flow rate through the Diskus™/Accuhaler™ inhaler and Turbuhaler™ inhaler in children with asthma. ERS Ann. Congress Barcelona, P2107.
15. Malton, A., Sumby, B.S., Smith, I.J., 1995. A comparison of in vitro drug delivery from two multidose powder inhalation devices. Eur. J. Clin. Res. 7, 177-193.
16. Meijer, R.J., Van der Mark, Th.W., Aalders, B.J., Postma, D.S., Koeter, G.H., 1996. Home assessment of peak inspiratory flow through the Turbuhaler in asthmatic patients. Thorax 51, 433-434.
17. Newman, S.P., Morén, F., Trofast, E., Talaee, N., Clarke, S.W., 1989. Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler. Eur. Respir. J. 2, 247-252.
18. Olsson, B., 1995. Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers?. J. Aerosol Med. 8 (Suppl 3), S13-S19.
19. Prime, D., Parkes, P.A., Petchey, L., Slater, A.L., Woodhouse, R.N., 1996. Evaluation of the pharmaceutical performance of two dry powder inhalers: comparison of Diskus™ and Turbuhaler™ inhalers. Am. J. Respir. Crit. Care Med. 153, A62.
20. Timsina, M.P., Martin, G.P., Marriott, C., Lee, K.C., Suen, K.O., Yianneskis, M., 1993. Studies on the measurement of peak inspiratory flow rate (PIF) with dry powder inhaler devices in healthy volunteers. Thorax 48, 433.
21. Timsina, M.P., Martin, G.P., Marriott, C., Ganderton, D., Yianneskis, M., 1994. Drug delivery to the respiratory tract using dry powder inhalers. Int. J. Pharm. 101, 1-13.
22. Wetterlin, K., 1988. Turbuhaler: a new dry powder inhaler for administration of drugs to the airways. Pharm. Res. 5, 506-508.